Oral Administration System Based on Meloxicam Nanocrystals: Decreased Dose Due to High Bioavailability Attenuates Risk of Gastrointestinal Side Effects

Meloxicam (MLX) is widely applied as a therapy for rheumatoid arthritis (RA); however, it takes far too long to reach its peak plasma concentration for a quick onset effect, and gastrointestinal toxicity has been observed in RA patients taking it. To solve these problems, we designed MLX solid nanop...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Noriaki, Ogata, Fumihiko, Otake, Hiroko, Kawasaki, Naohito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238067/
https://www.ncbi.nlm.nih.gov/pubmed/32244754
http://dx.doi.org/10.3390/pharmaceutics12040313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238067/
https://www.ncbi.nlm.nih.gov/pubmed/32244754
http://dx.doi.org/10.3390/pharmaceutics12040313

Ejemplares similares